Pharma's Market
SPECIAL REPORT
MOST SHARED
- Spain to Inject 19 Billion Euros into Bankia
- Fresh Fears as EU Finalises Reform Plans
- Beijing Faces Brussels Action on Telecoms Aid
- Zero China Growth Is ‘Probable’: Gordon Chang
- Citigroup Lost $20 Million on Facebook IPO Trades
- China Growth Risks Signal Need for Fiscal Action
- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- What Would Greek Exit Mean for the US Economy?
- GM Discloses $600,000 Contract With Ad Agency Tied to CFO's Wife
- 5 High-Yield Stocks Ready to Boost Dividends
- A New Look at the ‘New Poor’
- Six Pack: Beer Buzz of the Week
- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- Under Pressure, FHA Skews to Wealthier Home Buyers
- Big Stock Upside for Hudson City Deal: Analyst
- 5 High-Yield Stocks Ready to Boost Dividends
- Yoshikami: Four Things You Need to Know About Gold Now
- Steinbock: The Euro Zone Endgame Begins
- Option Bulls Take Another Shot on Idenix
- Citigroup Lost $20 Million on Facebook IPO Trades
- JPMorgan to Shake Up Risk Team After Big Loss: Report
- EU Finalizes Bank Reforms; Shifts Burden to Bondholders
- Spain to Inject Emergency 19 Billion Euros into Bankia
- EU Set to Launch Action Against China Over Telecom Aid
- JPMorgan to Shake Up Risk Team After Big Loss: Report
- Marc Faber: Chance of Global Recession Is Now 100%
- Cool Jobs: From Gold Stacker to Bed Tester
- 'Flash Sale' Sites: Gimmick, or Online Shopping Future?
RSS FEED
Regulatory "Risky Business" for Pharma & Biotech
Text Size 
Reporter
 |
CNBC.com |
] and Schering-Plough [SGP
Loading...
()
] announced that the Food and Drug Administration won't approve their combo Claritin-Singulair combo pill for allergies.Analysts didn't have high hopes for the drug (especially after the agency recently revealed it's investigating a possible association between Singulair and suicidal behavior), so investors seem to be shrugging off the news.
In fact, MRK shares are rallying this morning ahead of an anticipated FDA decision sometime today on its cholesterol drug called Cordaptive. It's a combo of Niacin and a special ingredient to reduce the facial flushing side effects of Niacin. Analyst estimates for peak sales of Cordaptive range from a few hundred million bucks a year to billion-dollar blockbuster status.
Abbott Labs [ABT
Loading...
()
] makes a Niacin drug called Niaspan which could possibly take a hit if/when Cordaptive gets approved. Today is the date given as the PDUFA (Prescription Drug User Fee Act) or what, in plain English, I like to call the"action day" for an FDA Cordaptive decision in case you're wondering how people know when this kind of stuff is gonna happen.
Also late Friday, Bristol-Myers Squibb [BMY
Loading...
()
] and Medarex [MEDX
Loading...
()
] announced a regulatory delay for their skin cancer treatment. MEDX shares hit a new intra-day low earlier this morning. The FDA wants the companies to test and see if the drug helps people live longer rather than just extending the amount of time that goes by before the cancer worstens.
Meantime, after dueling data presentations at a scientific conference in Milan over the weekend, analysts are declaring Vertex Pharmaceuticals [VRTX
Loading...
()
] the winner versus Schering-Plough in the latest round of the Hepatitis C drug battle. Vertex is partnered with Johnson and Johnson [JNJ
Loading...
()
] on telaprevir. Wachovia's George Farmer calls SGP's data "underwhelming" and says VRTX's data "positions telaprevir as the (Hepatitis C drug) of choice between these two candidates." Leerink Swann's Howard Liang says Schering's drug is "in the game" but adds, "Advantage goes to telaprevir."
Hep C doesn't get much mainstream media play, but in medical and investment circles it is considered to be a big area of unmet need and a potential goldmine for drug companies that can develop better treatments. The drugs on the market today don't work on many patients and can make them feel like they have the flu. VRTX and SGP have the most mature pipeline products, but other companies are also in various earlier stages of developing Hep C drugs.
Wachovia and Leerink Swann make a market in VRTX and LS trades in SGP.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes
